AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$ROIV

Epperly Melissa B, sold $641K of ROIV

Epperly Melissa B, sold 17,750 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.10 ($36.08–$36.57, $0.64M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Epperly Melissa B,
Published Oct 5, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Bearish
medium confidence
Mentioned
$ROIV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVBearishLow
01

Why it matters

The director's sale reduces insider ownership, which may be interpreted as a lack of confidence, but the pre‑arranged nature tempers the signal.

02

Market read

The filing provides fresh, material information about insider ownership, offering a modest trading signal for ROIV.

03

What to watch

Potential upcoming clinical data releases or partnership news could offset the sell pressure.

Relevance 4/10Novelty 4/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ROIVBearishMedium confidence
Context

Director Melissa Epperly sold 17,750 shares for $640,861 via a 10b5‑1 plan, reducing her stake to 14,954 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

A director sold over $600k of stock under a pre‑arranged plan; such sales often signal limited confidence and can prompt short‑term price dips.

Market effects

Sector

Minimal impact on the broader biotech sector; insider sales are company‑specific.

Regional

No significant regional effect; the filing is isolated to ROIV.

Global

Limited global relevance; only relevant to investors tracking ROIV.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not indicative of future performance.

Key entities

  • Company
    Roivant Sciences Ltd.

    Biopharma company listed on Nasdaq under ticker ROIV.

  • Individual
    Melissa Epperly

    Director of Roivant Sciences Ltd., reporting the insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 5
$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

benzinga.com3 min
OCT 5
Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

biospace.com3 min
SEP 24
$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

insidermonkey.com3 min